|
First, Know Thyself: A Self-Assessment Program on Management of Bladder Cancer
Hematology-Oncology
Curriculum:
First, Know Thyself: A Self-Assessment Program on Management of Bladder Cancer
First, Know Thyself: A Self-Assessment Program on Management of Bladder Cancer
Credits:
0.75 AMA PRA Category 1 Credit(s) ™
0.75 AMA PRA Category 1 Credit(s) ™
Launch Date:
July 07, 2016
July 07, 2016
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Hematology-oncology and urology physicians
Relevant Terms:
Urothelial bladder cancer, bladder cancer
Yu-Ning Wong, MD, MSCE
Yu-Ning Wong, MD, MSCE
Associate Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, PA
Bio
Yu-Ning Wong, MD, MSCE, is currently an associate professor in the Department of Hematology/Oncology at the Fox Chase Cancer Center, part of the Temple University Health System in Philadelphia. She received her undergraduate degree from the University of Virginia and her MD from University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School (now Rutgers University). Dr. Wong trained in internal medicine at Thomas Jefferson University Hospital and in hematology/oncology at the Fox Chase Cancer Center/Temple University program. She also received a Master of Science in Clinical Epidemiology from the University of Pennsylvania.
Dr. Wong joined the faculty of the Fox Chase Cancer Center in 2005 and has an active clinical and translational research career as well as a busy practice caring for patients with urologic cancers. Her clinical research focuses on studying novel agents for advanced urologic cancers, including urothelial, renal, and prostate cancers. Her grant-funded research has focused on the uptake and outcomes of novel cancer treatments.
| 1. | Appropriately utilize currently approved treatments for advanced or metastatic urothelial bladder cancer to optimize patient outcomes | 2. | Incorporate neoadjuvant chemotherapy into the multidisciplinary management of patients with advanced or metastatic urothelial bladder cancer |
| 3. | Describe how emerging immunotherapies can be incorporated for management of patients with advanced or metastatic urothelial bladder cancer | 4. | Employ a strong patient-provider collaborative approach to managing patients with advanced or metastatic urothelial bladder cancer that includes patient education, engagement, and shared decision-making |
| 1. | Appropriately utilize currently approved treatments for advanced or metastatic urothelial bladder cancer to optimize patient outcomes |
| 2. | Incorporate neoadjuvant chemotherapy into the multidisciplinary management of patients with advanced or metastatic urothelial bladder cancer |
| 3. | Describe how emerging immunotherapies can be incorporated for management of patients with advanced or metastatic urothelial bladder cancer |
| 4. | Employ a strong patient-provider collaborative approach to managing patients with advanced or metastatic urothelial bladder cancer that includes patient education, engagement, and shared decision-making |
PHYSICIAN CONTINUING MEDICAL EDUCATION
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
- Yu-Ning Wong, MD, MSCE, has affiliations with Pfizer, PhRMA, and Tokai (Research).
RMEI Medical Education, LLC
- Marie Becker, PhD, has no affiliations with commercial interests to disclose.
- Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
- Amy Reeve has no affiliations with commercial interests to disclose.
Postgraduate Institute for Medicine
The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Estimated time to complete: .75 hours
Medium: Internet
Medium: Internet
FEE INFORMATION
There is no fee for this educational activity.
COMMERCIAL SUPPORT
This activity is supported by an independent educational grant from Genentech.
HOW TO RECEIVE CREDIT
By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive up to .75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the activity evaluation.
Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6.0+ for Mac OSX 10.7 and above |
© 2007-2024 HealthCourse, Inc. All rights reserved.
